1
|
Landi L, Delmonte A, Bonetti A, Pasello G, Metro G, Mazzoni F, Borra G, Giannarelli D, Andrikou K, Mangiola D, Gori S, D'Andrea MR, Minuti G, Resuli B, Laudisi A, Vidiri A, Conti L, Cappuzzo F. Combi-TED: a new trial testing Tedopi ® with docetaxel or nivolumab in metastatic non-small-cell lung cancer progressing after first line. Future Oncol 2022; 18:4457-4464. [PMID: 36946237 DOI: 10.2217/fon-2022-0913] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/23/2023] Open
Abstract
Despite the positive results obtained by first-line chemoimmunotherapy in patients with metastatic non-small-cell lung cancer (NSCLC), only a few second-line options are available after disease progression. Combi-TED is a phase II international study that will assess the efficacy of Tedopi®, a cancer vaccine, combined with either docetaxel or nivolumab and compared with docetaxel monotherapy in patients with metastatic NSCLC after chemoimmunotherapy. The study, currently in the recruitment phase, will assess 1-year overall survival (primary end point), patient's progression-free survival and overall response rate, as well as the correlation of efficacy with several tumor or blood biomarkers. The results will hopefully provide more information on Tedopi combinational treatment compared with current standard of care in NSCLC patients who fail first-line chemoimmunotherapy. Clinical Trial Registration: NCT04884282 (ClinicalTrials.gov).
Collapse
Affiliation(s)
- Lorenza Landi
- Istituto Nazionale Tumori 'Regina Elena' - Via Elio Chianesi n. 53, Roma (RM), 00144, Italy
| | - Angelo Delmonte
- Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori' (IRST) - Via Piero Maroncelli n. 40, Meldola (FC), 47014, Italy
| | - Andrea Bonetti
- Azienda ULSS 9 Scaligera - Ospedale Mater Salutis Legnago - Via Gianella n.1, Legnago (VR), 37045, Italy
| | - Giulia Pasello
- Department of Surgery, Oncology, & Gastroenterology, University of Padova - Via Giustiniani n. 2 - Padova (PD), 35124, Italy
- Istituto Oncologico Veneto, Via Gattamelata n. 64, Padova (PD), 35128, Italy
| | - Giulio Metro
- Ospedale Santa Maria della Misericordia - Azienda Ospedaliera di Perugia - Via Dottori n. 1, Perugia (PG), 06132, Italy
| | - Francesca Mazzoni
- Azienda Ospedaliero-Universitaria Careggi - Largo G.A. Brambilla n. 3, Firenze (FI), 50134, Italy
| | - Gloria Borra
- Azienda Ospedaliera Universitaria 'Maggiore della Carità' - C.so Mazzini n. 18, Novara (NO), 28100, Italy
| | - Diana Giannarelli
- Biostatistics, Scientific Directorate, Fondazione Policlinico Universitario A. Gemelli, IRCCS - Largo Agostino Gemelli n. 8, Roma (RM) 00168, Italy
| | - Kalliopi Andrikou
- Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori' (IRST) - Via Piero Maroncelli n. 40, Meldola (FC), 47014, Italy
| | - Daniela Mangiola
- Azienda ULSS 9 Scaligera - Ospedale Mater Salutis Legnago - Via Gianella n.1, Legnago (VR), 37045, Italy
| | - Stefania Gori
- IRCCS Ospedale Sacro Cuore Don Calabria - Via Don A. Sempreboni n. 5, Negrar di Valpolicella (VR), 37024, Italy
| | | | - Gabriele Minuti
- Istituto Nazionale Tumori 'Regina Elena' - Via Elio Chianesi n. 53, Roma (RM), 00144, Italy
| | - Blerina Resuli
- Istituto Nazionale Tumori 'Regina Elena' - Via Elio Chianesi n. 53, Roma (RM), 00144, Italy
| | - Anastasia Laudisi
- Istituto Nazionale Tumori 'Regina Elena' - Via Elio Chianesi n. 53, Roma (RM), 00144, Italy
| | - Antonello Vidiri
- Istituto Nazionale Tumori 'Regina Elena' - Via Elio Chianesi n. 53, Roma (RM), 00144, Italy
| | - Laura Conti
- Istituto Nazionale Tumori 'Regina Elena' - Via Elio Chianesi n. 53, Roma (RM), 00144, Italy
| | - Federico Cappuzzo
- Istituto Nazionale Tumori 'Regina Elena' - Via Elio Chianesi n. 53, Roma (RM), 00144, Italy
| |
Collapse
|
2
|
Gacci M, Marchioni M, DE Francesco P, Natoli C, Calabrò F, Losanno T, Gianmartin C, Serni S, Doni L, DE Nunzio C, DE Tursi M, Valeriani M, Giacinti S, Álvarez-Maestro M, Scarcia M, Ludovico GM, Del Bene G, Simone G, Ferriero M, Tuderti G, Bove P, Laudisi A, Carrieri G, Cormio L, Verze P, LA Rocca R, Falsaperla M, Frantellizzi V, Greco F, DI Nicola M, Schips L, Cindolo L. Enzalutamide in patients with castration-resistant prostate cancer: retrospective, multicenter, real life study. Minerva Urol Nephrol 2020; 73:489-497. [PMID: 32748613 DOI: 10.23736/s2724-6051.20.03723-6] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
BACKGROUND Metastatic castration-resistant prostate cancer (mCRPC) is the final stage of pCa history and represents a clinically relevant phenotype with an elevated burden of mortality. The aim of the present study was to evaluate the efficacy and safety of enzalutamide in a "real-life" setting in mCRPC patients. METHODS Data about all mCRPC patients treated with enzalutamide from September 2017 to September 2018 were collected. Demographics, comorbidities, clinical parameters, outcomes, toxicity, overall survival and progression free survival were analyzed. RESULTS Overall, 158 patients were enrolled. Mean age was 75.8 (±8.7) years with a baseline median PSA of 16.5 (IQR 7.4-47.8) ng/mL. The median follow-up lasted 7.7 (IQR 4-14.1) months. Of all the 10.1% of patients reported grade 3-4 adverse events. 43.7% of patients experienced a progression. Overall, the 6 and 12 months PFS rates were 69.5% (95% CI: 61.7-78.3%) and the 45.6% (95% CI: 36.5-57.1%); a median baseline PSA>16 ng/mL (HR:2.0, 95% CI: 1.2-3.3, P<0.005), the use of opioid (HR: 3.1, 95% CI: 1.9-5.0, P<0.001), a previous treatment (abiraterone, docetaxel or abiraterone + docetaxel) were significantly associated with higher rates of cancer progression. Conversely, a brief pain questionnaire of 0-1 (HR: 0.4, 95% CI: 0.2-0.7, P<0.001), a 12 weeks 50% PSA reduction (HR: 0.4, 95% CI: 0.2-0.8, P<0.006) and a longer time to mCRPC (HR: 0.4, 95% CI: 0.3-0.7, P<0.002) were related to lower cancer progression rates. CONCLUSIONS Our data shows an effective and safe profile of enzalutamide in a "real world" perspective in patients with mcRPC.
Collapse
Affiliation(s)
- Mauro Gacci
- Department of Minimally Invasive and Robotic Urologic Surgery and Kidney Transplantation, AOUC Careggi Hospital, Florence, Italy
| | - Michele Marchioni
- Department of Medical, Oral and Biotechnological Sciences, Laboratory of Biostatistics, G. D'Annunzio University, Chieti, Chieti-Pescara, Italy
| | | | - Clara Natoli
- Department of Medical, Oral and Biotechnological Sciences, Medical Oncology, G. D'Annunzio University, Chieti, Chieti-Pescara, Italy
| | - Fabio Calabrò
- Department of Medical Oncology, San Camillo-Forlanini Hospital, Rome, Italy
| | - Tania Losanno
- Department of Medical Oncology, San Camillo-Forlanini Hospital, Rome, Italy
| | - Cito Gianmartin
- Department of Minimally Invasive and Robotic Urologic Surgery and Kidney Transplantation, AOUC Careggi Hospital, Florence, Italy
| | - Sergio Serni
- Department of Minimally Invasive and Robotic Urologic Surgery and Kidney Transplantation, AOUC Careggi Hospital, Florence, Italy
| | - Laura Doni
- Department of Medical Oncology, Careggi University Hospital, Florence, Italy
| | - Cosimo DE Nunzio
- Department of Urology, Sant'Andrea Hospital, Sapienza University, Rome, Italy
| | - Michele DE Tursi
- Department of Medical, Oral and Biotechnological Sciences, Medical Oncology, G. D'Annunzio University, Chieti, Chieti-Pescara, Italy
| | - Maurizio Valeriani
- Unit of Radiation Therapy, Sant'Andrea Hospital, Sapienza University, Rome, Italy
| | - Silvana Giacinti
- Unit of Oncology, Sant'Andrea Hospital, Sapienza University, Rome, Italy
| | | | | | | | - Gabriella Del Bene
- Department of Medical Oncology, San Camillo-Forlanini Hospital, Rome, Italy
| | - Giuseppe Simone
- Department of Urology, Regina Elena National Cancer Institute, Rome, Italy
| | | | - Gabriele Tuderti
- Department of Urology, Regina Elena National Cancer Institute, Rome, Italy
| | - Pierluigi Bove
- Department of Experimental Medicine and Surgery, Tor Vergata Polyclinic, Rome, Italy.,Unit of Urology, San Carlo di Nancy Hospital, Rome, Italy
| | | | | | - Luigi Cormio
- Department of Urology, University of Foggia, Foggia, Italy
| | - Paolo Verze
- Unit of Urology, Department of Neurosciences, Sciences of Reproduction and Odontostomatology, Federico II University, Naples, Italy
| | - Roberto LA Rocca
- Unit of Urology, Department of Neurosciences, Sciences of Reproduction and Odontostomatology, Federico II University, Naples, Italy
| | - Mario Falsaperla
- Department of Urology, Vittorio Emanuele Polyclinic, Catania, Italy
| | | | - Francesco Greco
- Department of Urology, Humanitas Gavazzeni Hospital, Bergamo, Italy
| | - Marta DI Nicola
- Department of Medical, Oral and Biotechnological Sciences, Laboratory of Biostatistics, G. D'Annunzio University, Chieti, Chieti-Pescara, Italy
| | - Luigi Schips
- Department of Urology, ASL Abruzzo2, Chieti, Italy.,Department of Medical, Oral and Biotechnological Sciences, Department of Urology, G. D'Annunzio University, Chieti, Chieti-Pescara, Italy
| | - Luca Cindolo
- Department of Urology, ASL Abruzzo2, Chieti, Italy -
| |
Collapse
|
3
|
Gacci M, Marchioni M, DE Francesco P, Natoli C, Calabrò F, Losanno T, Gianmartin C, Serni S, Doni L, DE Nunzio C, DE Tursi M, Valeriani M, Giacinti S, Álvarez-Maestro M, Scarcia M, Ludovico GM, Del Bene G, Simone G, Ferriero M, Tuderti G, Bove P, Laudisi A, Carrieri G, Cormio L, Verze P, LA Rocca R, Falsaperla M, Frantellizzi V, Greco F, DI Nicola M, Schips L, Cindolo L. Enzalutamide in patients with castration-resistant prostate cancer: retrospective, multicenter, real life study. Minerva Urol Nephrol 2020. [PMID: 32748613 DOI: 10.23736/s0393-2249.20.03723-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
BACKGROUND Metastatic castration-resistant prostate cancer (mCRPC) is the final stage of pCa history and represents a clinically relevant phenotype with an elevated burden of mortality. The aim of the present study was to evaluate the efficacy and safety of enzalutamide in a "real-life" setting in mCRPC patients. METHODS Data about all mCRPC patients treated with enzalutamide from September 2017 to September 2018 were collected. Demographics, comorbidities, clinical parameters, outcomes, toxicity, overall survival and progression free survival were analyzed. RESULTS Overall, 158 patients were enrolled. Mean age was 75.8 (±8.7) years with a baseline median PSA of 16.5 (IQR 7.4-47.8) ng/mL. The median follow-up lasted 7.7 (IQR 4-14.1) months. Of all the 10.1% of patients reported grade 3-4 adverse events. 43.7% of patients experienced a progression. Overall, the 6 and 12 months PFS rates were 69.5% (95% CI: 61.7-78.3%) and the 45.6% (95% CI: 36.5-57.1%); a median baseline PSA>16 ng/mL (HR:2.0, 95% CI: 1.2-3.3, P<0.005), the use of opioid (HR: 3.1, 95% CI: 1.9-5.0, P<0.001), a previous treatment (abiraterone, docetaxel or abiraterone + docetaxel) were significantly associated with higher rates of cancer progression. Conversely, a brief pain questionnaire of 0-1 (HR: 0.4, 95% CI: 0.2-0.7, P<0.001), a 12 weeks 50% PSA reduction (HR: 0.4, 95% CI: 0.2-0.8, P<0.006) and a longer time to mCRPC (HR: 0.4, 95% CI: 0.3-0.7, P<0.002) were related to lower cancer progression rates. CONCLUSIONS Our data shows an effective and safe profile of enzalutamide in a "real world" perspective in patients with mcRPC.
Collapse
Affiliation(s)
- Mauro Gacci
- Department of Minimally Invasive and Robotic Urologic Surgery and Kidney Transplantation, AOUC Careggi Hospital, Florence, Italy
| | - Michele Marchioni
- Department of Medical, Oral and Biotechnological Sciences, Laboratory of Biostatistics, G. D'Annunzio University, Chieti, Chieti-Pescara, Italy
| | | | - Clara Natoli
- Department of Medical, Oral and Biotechnological Sciences, Medical Oncology, G. D'Annunzio University, Chieti, Chieti-Pescara, Italy
| | - Fabio Calabrò
- Department of Medical Oncology, San Camillo-Forlanini Hospital, Rome, Italy
| | - Tania Losanno
- Department of Medical Oncology, San Camillo-Forlanini Hospital, Rome, Italy
| | - Cito Gianmartin
- Department of Minimally Invasive and Robotic Urologic Surgery and Kidney Transplantation, AOUC Careggi Hospital, Florence, Italy
| | - Sergio Serni
- Department of Minimally Invasive and Robotic Urologic Surgery and Kidney Transplantation, AOUC Careggi Hospital, Florence, Italy
| | - Laura Doni
- Department of Medical Oncology, Careggi University Hospital, Florence, Italy
| | - Cosimo DE Nunzio
- Department of Urology, Sant'Andrea Hospital, Sapienza University, Rome, Italy
| | - Michele DE Tursi
- Department of Medical, Oral and Biotechnological Sciences, Medical Oncology, G. D'Annunzio University, Chieti, Chieti-Pescara, Italy
| | - Maurizio Valeriani
- Unit of Radiation Therapy, Sant'Andrea Hospital, Sapienza University, Rome, Italy
| | - Silvana Giacinti
- Unit of Oncology, Sant'Andrea Hospital, Sapienza University, Rome, Italy
| | | | | | | | - Gabriella Del Bene
- Department of Medical Oncology, San Camillo-Forlanini Hospital, Rome, Italy
| | - Giuseppe Simone
- Department of Urology, Regina Elena National Cancer Institute, Rome, Italy
| | | | - Gabriele Tuderti
- Department of Urology, Regina Elena National Cancer Institute, Rome, Italy
| | - Pierluigi Bove
- Department of Experimental Medicine and Surgery, Tor Vergata Polyclinic, Rome, Italy.,Unit of Urology, San Carlo di Nancy Hospital, Rome, Italy
| | | | | | - Luigi Cormio
- Department of Urology, University of Foggia, Foggia, Italy
| | - Paolo Verze
- Unit of Urology, Department of Neurosciences, Sciences of Reproduction and Odontostomatology, Federico II University, Naples, Italy
| | - Roberto LA Rocca
- Unit of Urology, Department of Neurosciences, Sciences of Reproduction and Odontostomatology, Federico II University, Naples, Italy
| | - Mario Falsaperla
- Department of Urology, Vittorio Emanuele Polyclinic, Catania, Italy
| | | | - Francesco Greco
- Department of Urology, Humanitas Gavazzeni Hospital, Bergamo, Italy
| | - Marta DI Nicola
- Department of Medical, Oral and Biotechnological Sciences, Laboratory of Biostatistics, G. D'Annunzio University, Chieti, Chieti-Pescara, Italy
| | - Luigi Schips
- Department of Urology, ASL Abruzzo2, Chieti, Italy.,Department of Medical, Oral and Biotechnological Sciences, Department of Urology, G. D'Annunzio University, Chieti, Chieti-Pescara, Italy
| | - Luca Cindolo
- Department of Urology, ASL Abruzzo2, Chieti, Italy -
| |
Collapse
|
4
|
Ferroni P, Roselli M, Buonomo OC, Spila A, Portarena I, Laudisi A, Valente MG, Pirillo SP, Fortunato L, Costarelli L, Cavaliere F, Guadagni F. Prognostic Significance of Neutrophil-to-lymphocyte Ratio in the Framework of the 8th TNM Edition for Breast Cancer. Anticancer Res 2018; 38:4705-4712. [PMID: 30061239 DOI: 10.21873/anticanres.12777] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2018] [Revised: 07/01/2018] [Accepted: 07/05/2018] [Indexed: 11/10/2022]
Abstract
BACKGROUND/AIM To investigate whether neutrophil-to-lymphocyte ratio (NLR) might represent an additional biological criterion able to identify patients with worse prognosis within the 8th edition TNM prognostic staging system for breast cancer (BC). PATIENTS AND METHODS Pre-treatment NLR was retrospectively analyzed in 475 BC women prospectively followed for a mean time of 3.8 years. The optimal NLR cutoff, identified by ROC analysis, was set at 2. RESULTS Elevated pre-treatment NLR was associated with worse disease-free survival (DFS) (HR=2.28) and overall survival (OS) (HR=3.39). The prognostic value of NLR was mostly evident in stage I BC (HR for DFS=2.89; HR for OS=1.30), in whom NLR significantly stratified patients who developed distant metastasis (HR= 4.62), but not local recurrence. CONCLUSION NLR might provide important information in risk stratification, especially in stage I BC patients in whom the presence of a high NLR might raise the question as to whether they should be more aggressively managed.
Collapse
Affiliation(s)
- Patrizia Ferroni
- Department of Human Sciences and Quality of Life Promotion, San Raffaele Roma Open University, Rome, Italy .,Interinstitutional Multidisciplinary Biobank (BioBIM), IRCCS San Raffaele Pisana, Rome, Italy
| | - Mario Roselli
- Department of Systems Medicine, Medical Oncology, Policlinico Tor Vergata Biospecimen Cancer Repository (PTV Bio.Ca.Re.), Tor Vergata University of Rome, Rome, Italy
| | - Oreste C Buonomo
- Department of Surgery, Tor Vergata University of Rome, Rome, Italy
| | - Antonella Spila
- Interinstitutional Multidisciplinary Biobank (BioBIM), IRCCS San Raffaele Pisana, Rome, Italy
| | - Ilaria Portarena
- Department of Systems Medicine, Medical Oncology, Policlinico Tor Vergata Biospecimen Cancer Repository (PTV Bio.Ca.Re.), Tor Vergata University of Rome, Rome, Italy
| | - Anastasia Laudisi
- Department of Systems Medicine, Medical Oncology, Policlinico Tor Vergata Biospecimen Cancer Repository (PTV Bio.Ca.Re.), Tor Vergata University of Rome, Rome, Italy
| | - Maria G Valente
- Interinstitutional Multidisciplinary Biobank (BioBIM), IRCCS San Raffaele Pisana, Rome, Italy
| | - Silvana P Pirillo
- Department of Radiology, San Giovanni Hospital-Addolorata, Rome, Italy
| | | | | | - Francesco Cavaliere
- Breast Unit, San Giovanni Hospital-Addolorata, Rome, Italy.,Breast Unit, Belcolle Hospital, Viterbo, Italy
| | - Fiorella Guadagni
- Department of Human Sciences and Quality of Life Promotion, San Raffaele Roma Open University, Rome, Italy.,Interinstitutional Multidisciplinary Biobank (BioBIM), IRCCS San Raffaele Pisana, Rome, Italy
| |
Collapse
|
5
|
Cindolo L, Natoli C, De Nunzio C, De Tursi M, Valeriani M, Giacinti S, Micali S, Rizzo M, Bianchi G, Martorana E, Scarcia M, Ludovico GM, Bove P, Laudisi A, Selvaggio O, Carrieri G, Bada M, Castellan P, Boccasile S, Ditonno P, Chiodini P, Verze P, Mirone V, Schips L. Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: an Italian multicenter "real life" study. BMC Cancer 2017; 17:753. [PMID: 29126389 PMCID: PMC5681753 DOI: 10.1186/s12885-017-3755-x] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2017] [Accepted: 11/06/2017] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND To evaluate the safety and efficacy of abiraterone acetate (AA) in the "real life" clinical practice for men with chemotherapy-naïve metastatic castration-resistant prostate. METHODS A consecutive series of patients with mCRPC in 9 Italian tertiary centres treated with AA was collected. Demographics, clinical parameters, treatment outcomes and toxicity were recorded. The Brief Pain Inventory scale Q3 was tracked and patient treatment satisfaction was evaluated. Survival curves were estimated by the method of Kaplan-Meier and Cox regression and compared by the log-rank test statistic. RESULTS We included 145 patients (mean age 76.5y). All patients were on androgen deprivation therapy. Patients had prior radiotherapy, radical prostatectomy, both treatments or exclusive androgen deprivation therapy in 17%, 33%, 9% and 40%, respectively. 57% of the patients had a Gleason score higher more than 7 at diagnosis. 62% were asymptomatic patients. The median serum total PSA at AA start was 17 ng/mL (range 0,4-2100). The median exposure to AA was 10 months (range 1-35). The proportion of patients achieving a PSA decline ≥50% at 12 weeks was 49%. Distribution of patient satisfaction was 32% "greatly improved", 38% "improved", 24% "not changed", 5.5% "worsened". Grade 3 and 4 toxicity was recorded in 17/145 patients 11.7% (70% cardiovascular events, 30% critical elevation of AST/ALT levels). At the last follow-up, median progression free and overall survival were 17 and 26.5 months, respectively. Both outcomes significantly correlated with the presence of pain, patient satisfaction, PSA baseline and PSA decline. CONCLUSIONS The AA is effective and well tolerated in asymptomatic or slightly symptomatic mCRPC in a "real life" setting. The survival outcomes are influenced by the presence of pain, patient satisfaction, baseline PSA and PSA decline. TRIAL REGISTRATION The study was retrospectively registered at ISRCTN as DOI: 10.1186/ISRCTN 52513758 in date April the 30th 2016.
Collapse
Affiliation(s)
- Luca Cindolo
- Department of Urology, ASL Abruzzo2, Via dei Vestini, Chieti, Italy. .,Department of Urology, ASL Abruzzo2 , "S. Pio da Pietrelcina" Hospital, Via San Camillo de Lellis 1, Vasto, Italy.
| | - Clara Natoli
- Department of Medical, Oral and Biotechnological Sciences, Centro Scienze dell'Invecchiamento e Medicina Traslazionale (CeSI-MeT), Chieti, Italy
| | - Cosimo De Nunzio
- Department of Urology, "Sant'Andrea" Hospital , Sapienza University", Rome, Italy
| | - Michele De Tursi
- Department of Medical, Oral and Biotechnological Sciences, Centro Scienze dell'Invecchiamento e Medicina Traslazionale (CeSI-MeT), Chieti, Italy
| | - Maurizio Valeriani
- Radiation therapy Unit, "Sant'Andrea" Hospital, "Sapienza University", Rome, Italy
| | - Silvana Giacinti
- Oncology Unit, "Sant'Andrea" Hospital, "Sapienza University", Rome, Italy
| | - Salvatore Micali
- Department of Urology, University of Modena & Reggio Emilia, Baggiovara Hospital, Via Giardini, 1355, Baggiovara, Italy
| | - Mino Rizzo
- Department of Urology, University of Modena & Reggio Emilia, Baggiovara Hospital, Via Giardini, 1355, Baggiovara, Italy
| | - Giampaolo Bianchi
- Department of Urology, University of Modena & Reggio Emilia, Baggiovara Hospital, Via Giardini, 1355, Baggiovara, Italy
| | - Eugenio Martorana
- Department of Urology, University of Modena & Reggio Emilia, Baggiovara Hospital, Via Giardini, 1355, Baggiovara, Italy
| | - Marcello Scarcia
- Ente Ecclesiastico Ospedale "F. Miulli", S.P. per Santeramo Km 4.100, Acquaviva delle Fonti, Italy
| | - Giuseppe Mario Ludovico
- Ente Ecclesiastico Ospedale "F. Miulli", S.P. per Santeramo Km 4.100, Acquaviva delle Fonti, Italy
| | - Pierluigi Bove
- Department Of Experimental Medicine and Surgery, Azienda Policlinico Tor Vergata, Rome, Italy
| | - Anastasia Laudisi
- UOSD of Medical Oncology Azienda Policlinico Tor Vergata, Rome, Italy
| | - Oscar Selvaggio
- Department of Urology, University of Foggia, V.le L. Pinto, Foggia, Italy
| | - Giuseppe Carrieri
- Department of Urology, University of Foggia, V.le L. Pinto, Foggia, Italy
| | - Maida Bada
- Department of Urology, ASL Abruzzo2, Via dei Vestini, Chieti, Italy
| | - Pietro Castellan
- Department of Urology, ASL Abruzzo2, Via dei Vestini, Chieti, Italy
| | - Stefano Boccasile
- Urology and Andrology Unit II, Department of Emergency and Organ Transplantation, University of Bari, Piazza G. Cesare 11, Bari, Italy
| | - Pasquale Ditonno
- Urology and Andrology Unit II, Department of Emergency and Organ Transplantation, University of Bari, Piazza G. Cesare 11, Bari, Italy
| | - Paolo Chiodini
- Medical Statistics Unit, University of Campania "Luigi Vanvitelli", via L. Armanni 5, Naples, Italy
| | - Paolo Verze
- Department of Neurosciences, Sciences of Reproduction and Odontostomatology, Urology Unit, University of Naples "Federico II", Naples, Italy
| | - Vincenzo Mirone
- Department of Neurosciences, Sciences of Reproduction and Odontostomatology, Urology Unit, University of Naples "Federico II", Naples, Italy
| | - Luigi Schips
- Department of Urology, ASL Abruzzo2, Via dei Vestini, Chieti, Italy
| |
Collapse
|
6
|
Formica V, Nardecchia A, Pellegrino R, Massimiliani V, Donnarumma L, Giuliano G, Renzi N, Mariotti S, Portarena I, Laudisi A, Morelli C, Lucchetti J, Perrone L, Riondino S, Roselli M. BMI and health-related quality of life (HR-QoL) in patients with metastatic colorectal cancer (mCRC). J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.31_suppl.249] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
249 Background: Relationship between BMI and HR-QoL has been extensively studied in CRC survivors. Increasing BMI has been recently associated with improved survival in mCRC pts, however data on the relationship between BMI and common HR-QoL measures in mCRC are scarce Methods: The EORTC QLC C30 and the NCCN distress thermometer (DT) and problem list (PL) questionnaires were administered to consecutive mCRC pts candidate for firstline chemotherapy. The effect of BMI on HR-QoL were analyzed using the Kruskal-Wallis and Mann-Whitney tests. The interaction between BMI and other variables of interest (such as inflammatory indexes) for the effect on HR-QoL was also analysed using a logistic regression analysis Results: Of 135 screened pts, 119 completed the questionnaires. A direct association was observed between BMI and GH score, with the score gradually improving from BMI 14 to 21, then plateauing between 21 and 41. A significantly lower GH was observed for BMI < 21 vs > 21 (GH 50 vs 67, p 0.014). DT and BMI were not correlated. BMI was inversely associated with practical problems (mean number of reported problems 0.7 vs 0.4 for BMI < 24 vs > 24, p0.012). The other components inversely associated with BMI were appetite loss, pain and fatigue (which were higher for BMI < 21 , p values 0.033, 0.015 and 0.007, respectively). A direct association with BMI was also observed for social and physical functioning (p values 0.002 and 0.05, respectively). Median BMI in pts with GH score < 25 vs > 25 was 19 vs 25, p 0.05. Percentage of pts with very low BMI (BMI < 21) was 38% vs 2% for pts with GH < 25 vs > 25, respectively, Odds Ratio 32.4, p 0.0007. Among 15 common clinical and biochemical analysed variables, the inflammatory index neutrophil/lymphocyte ratio (NLR) demonstrated a significant interaction with BMI for the effect on GH, with the direct association between BMI and GH only retained in pts with low NLR and a deteriorated GH in pts with high NLR regardless of BMI, test for interaction p 0.013 Conclusions: Low BMI is associated with deteriorated HR-QoL in mCRC pts with low NLR approaching a first-line treatment. Adequate nutritional support and anti-inflammatory approaches would improve HR-QoL in these pts.
Collapse
|
7
|
Mariotti S, Formica V, Pellegrino R, Nardecchia A, Lucchetti J, Morelli A, Laudisi A, Morelli C, Renzi N, Massimiliani V, Donnarumma L, Riondino S, Portarena I, Roselli M. Evaluation of QoL as a predictor of chemotherapy-induced toxicity. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx434.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
8
|
Cindolo L, Natoli C, De Nunzio C, De Tursi M, Valeriani M, Giacinti S, Micali S, Rizzo M, Bianchi G, Martorana E, Scarcia M, Ludovico GM, Bove P, Laudisi A, Selvaggio O, Carrieri G, Bada M, Castellan P, Topazio L, Boccasile S, Ditonno P, Chiodini P, Schips L. Abiraterone Acetate for Treatment of Metastatic Castration-resistant Prostate Cancer in Chemotherapy-naive Patients: An Italian Analysis of Patients' Satisfaction. Clin Genitourin Cancer 2017; 15:520-525. [PMID: 28478884 DOI: 10.1016/j.clgc.2017.04.003] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2017] [Revised: 03/20/2017] [Accepted: 04/03/2017] [Indexed: 01/22/2023]
Abstract
INTRODUCTION Abiraterone acetate (AA) gives a significant improvement in survival for patients with metastatic castration-resistant prostate cancer (mCRPC) before and after chemotherapy and has a favorable effect on patients' health-related quality of life and pain. Only a few studies have investigated patient-reported outcomes (PROs) in AA treatment for mCRPC. The aim of this study was to investigate patients' satisfaction in men affected by mCRPC treated with AA. MATERIALS AND METHODS This was a retrospective analysis of a database of consecutive chemonaive patients with progressive mCRPC. Patients were treated with AA until disease progression, death, or unacceptable toxicity. Evaluation was performed at baseline and every 4 weeks by means of physical examination and laboratory studies. Eastern Cooperative Oncology Group score, pain symptoms, treatment-related toxicity, prostate-specific antigen (PSA), and overall and progression-free survival were recorded. Satisfaction with treatment was investigated at 6 months by means of a 4-point arbitrary scale. RESULTS One-hundred twenty-eight patients were enrolled. Patients' satisfaction with treatment was "greatly improved" in 36.1% of patients and "improved" in 32.4% of them. Patients with higher satisfaction had lower baseline and final PSA values (P < .05), lower PSA levels at 12 weeks (P = .080), and less pain symptoms and lower Brief Pain Inventory scores (P = .001). Satisfaction with treatment was significantly correlated with baseline PSA level (P = .018), presence of pain (P = .007), duration of androgen deprivation therapy >12 months (P = .025), and number of hormonal manipulations (P = .051). Progression-free survival significantly correlated with patient satisfaction (P < .001). CONCLUSION AA is safe and well tolerated in chemonaive mCRPC patients, ensures good oncological and PROs. Patient's satisfaction is a predictor of progression-free survival.
Collapse
Affiliation(s)
- Luca Cindolo
- Department of Urology, ASL Abruzzo 2, Chieti, Italy
| | - Clara Natoli
- Department of Medical, Oral and Biotechnological Sciences, University "G. D'Annunzio" of Chieti-Pescara, Chieti, Italy
| | - Cosimo De Nunzio
- Department of Urology, "Sant'Andrea" Hospital, "Sapienza University", Roma, Italy
| | - Michele De Tursi
- Department of Medical, Oral and Biotechnological Sciences, University "G. D'Annunzio" of Chieti-Pescara, Chieti, Italy
| | - Maurizio Valeriani
- Radiation Therapy Unit, "Sant'Andrea" Hospital, "Sapienza University", Roma, Italy
| | - Silvana Giacinti
- Oncology Unit, "Sant'Andrea" Hospital, "Sapienza University", Roma, Italy
| | - Salvatore Micali
- Department of Urology, University of Modena and Reggio Emilia, Baggiovara Hospital, Baggiovara, Italy
| | - Mino Rizzo
- Department of Urology, University of Modena and Reggio Emilia, Baggiovara Hospital, Baggiovara, Italy
| | - Giampaolo Bianchi
- Department of Urology, University of Modena and Reggio Emilia, Baggiovara Hospital, Baggiovara, Italy
| | - Eugenio Martorana
- Department of Urology, University of Modena and Reggio Emilia, Baggiovara Hospital, Baggiovara, Italy
| | - Marcello Scarcia
- Ente Ecclesiastico Ospedale "F. Miulli", Acquaviva delle Fonti, Italy
| | | | - Pierluigi Bove
- Department of Experimental Medicine and Surgery, Azienda Policlinico Tor Vergata, Roma, Italy
| | - Anastasia Laudisi
- UOSD of Medical Oncology, Azienda Policlinico Tor Vergata, Roma, Italy
| | | | | | - Maida Bada
- Department of Urology, ASL Abruzzo 2, Chieti, Italy
| | | | - Luca Topazio
- Department of Experimental Medicine and Surgery, Azienda Policlinico Tor Vergata, Roma, Italy.
| | - Stefano Boccasile
- Urology and Andrology Unit II, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy
| | - Pasquale Ditonno
- Urology and Andrology Unit II, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy
| | - Paolo Chiodini
- Medical Statistics Unit, Second University of Naples, Naples, Italy
| | - Luigi Schips
- Department of Urology, ASL Abruzzo 2, Chieti, Italy
| |
Collapse
|
9
|
Ferroni P, Riondino S, Laudisi A, Portarena I, Formica V, Alessandroni J, D'Alessandro R, Orlandi A, Costarelli L, Cavaliere F, Guadagni F, Roselli M. Pretreatment Insulin Levels as a Prognostic Factor for Breast Cancer Progression. Oncologist 2016; 21:1041-9. [PMID: 27388232 DOI: 10.1634/theoncologist.2015-0462] [Citation(s) in RCA: 44] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2015] [Accepted: 02/09/2016] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND Based on the hypothesis that impaired glucose metabolism might be associated with survival outcomes independently of overt diabetes, we sought to investigate the prognostic value of routinely used glycemic parameters in a prospective study of breast cancer (BC) patients. PATIENTS AND METHODS Fasting blood glucose, insulin and HbA1c levels, and insulin resistance (assessed by the Homeostasis Model Assessment [HOMA] index) at diagnosis were evaluated in 286 nondiabetic BC patients (249 with primary cancer, 37 with metastatic) with respect to those parameters' possible associations with clinicopathological features and survival outcomes. As a control group, 143 healthy women matched in a 2:1 ratio for age, blood lipid levels, and body mass index were also investigated. RESULTS Fasting blood glucose level (mean ± SD: 99 ± 26 vs. 85 ± 15 mg/dL), insulin level (median: 10.0 vs. 6.8 μIU/mL), and HOMA index (median: 2.2 vs. 1.4), but not HbA1c level, were significantly elevated in BC patients compared with control subjects. Receiver operating characteristics analysis showed comparable areas for blood glucose and insulin levels, and HOMA index (ranging from 0.668 to 0.671). Using a cutoff level of 13 μIU/mL, insulin had the best specificity (92%) and sensitivity (41%), was significantly associated with disease stage, and acted as a negative prognostic marker of progression-free survival (hazard ratio: 2.17; 95% confidence interval: 1.13-4.20) independently of menopausal status, disease stage, hormone receptor status, and human epidermal growth factor receptor 2 and Ki67 expression. CONCLUSION These results suggest that insulin determination might provide prognostic information in BC and support the hypothesis that lifestyle and/or pharmacological interventions targeting glucose metabolism could be considered to improve survival outcome of selected BC patients. IMPLICATIONS FOR PRACTICE Pretreatment insulin levels may represent a biomarker of adverse prognosis in nondiabetic women with breast cancer, independently of other well-established prognostic factors (i.e., stage, hormone receptors, HER2/neu, and Ki67). This finding has important implications, because it provides the rationale for lifestyle or insulin-targeting pharmacologic interventions as a means of improving breast cancer outcomes not only in early stages, but also in advanced-stage breast cancer patients with aggressive tumor phenotypes (HER2-negative hormone-resistant, or triple-negative breast cancer), in which treatments are still challenging. The possibility of using insulin as a biomarker to guide insulin-targeted interventions also should be taken into account.
Collapse
Affiliation(s)
| | - Silvia Riondino
- Interinstitutional Multidisciplinary Biobank, Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele Pisana, Rome, Italy Department of Systems Medicine, Medical Oncology, Tor Vergata Clinical Center, Tor Vergata University of Rome, Rome, Italy
| | - Anastasia Laudisi
- Department of Systems Medicine, Medical Oncology, Tor Vergata Clinical Center, Tor Vergata University of Rome, Rome, Italy
| | - Ilaria Portarena
- Department of Systems Medicine, Medical Oncology, Tor Vergata Clinical Center, Tor Vergata University of Rome, Rome, Italy
| | - Vincenzo Formica
- Department of Systems Medicine, Medical Oncology, Tor Vergata Clinical Center, Tor Vergata University of Rome, Rome, Italy
| | - Jhessica Alessandroni
- Interinstitutional Multidisciplinary Biobank, Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele Pisana, Rome, Italy
| | - Roberta D'Alessandro
- Interinstitutional Multidisciplinary Biobank, Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele Pisana, Rome, Italy
| | - Augusto Orlandi
- Anatomic Pathology, Department of Biomedicine and Prevention, Tor Vergata University of Rome, Rome, Italy
| | | | | | - Fiorella Guadagni
- San Raffaele Roma Open University, Rome, Italy Interinstitutional Multidisciplinary Biobank, Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele Pisana, Rome, Italy
| | - Mario Roselli
- Department of Systems Medicine, Medical Oncology, Tor Vergata Clinical Center, Tor Vergata University of Rome, Rome, Italy
| |
Collapse
|
10
|
Ferroni P, Guadagni F, Laudisi A, Vergati M, Riondino S, Russo A, Davì G, Roselli M. Estimated glomerular filtration rate is an easy predictor of venous thromboembolism in cancer patients undergoing platinum-based chemotherapy. Oncologist 2014; 19:562-7. [PMID: 24710308 DOI: 10.1634/theoncologist.2013-0339] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Reduced estimated glomerular filtration rate (eGFR) has been associated with increased venous thromboembolism (VTE) risk in the general population. VTE incidence significantly increases in cancer patients, especially those undergoing chemotherapy. Despite the evidence that a substantial number of cancer patients have unrecognized renal impairment, as indicated by reduced eGFR in the presence of serum creatinine levels within the reference value, chemotherapy dosage is routinely adjusted for serum creatinine values. Among chemotherapies, platinum-based regimens are associated with the highest rates of VTE. A cohort study was designed to assess the value of pretreatment eGFR in the risk prediction of a first VTE episode in cancer outpatients without previous history of VTE who were scheduled for platinum-based chemotherapy. Methods. Serum creatinine and eGFR were evaluated before the start of standard platinum-based chemotherapy in a cohort of 322 consecutive patients with primary or relapsing/recurrent solid cancers, representative of a general practice population. Results. Patients who experienced a first VTE episode in the course of chemotherapy had lower mean eGFR values compared with patients who remained VTE free. Multivariate Cox analysis demonstrated that eGFR had an independent value for risk prediction of a first VTE episode during treatment, with a 3.15 hazard ratio. Indeed, 14% of patients with reduced eGFR had VTE over 1-year follow-up compared with 6% of patients with normal eGFR values. Conclusion. The results suggest that reductions in eGFR, even in the presence of normal serum creatinine, are associated with an increased VTE risk in cancer outpatients undergoing platinum-based chemotherapy regimens. Determining eGFR before chemotherapy could represent a simple predictor of VTE, at no additional cost to health care systems.
Collapse
Affiliation(s)
- Patrizia Ferroni
- Biomarker Discovery and Advanced Technologies (BioDAT) Laboratory, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Pisana-Research Center, Rome, Italy; Department of System Medicine, Medical Oncology, Tor Vergata Clinical Center, University of Rome "Tor Vergata," Rome, Italy; Section of Medical Oncology, Department of Surgical and Oncology Sciences, University of Palermo, Palermo, Italy; Internal Medicine and Center of Excellence on Aging, "G. d'Annunzio" University Foundation, Chieti, Italy
| | | | | | | | | | | | | | | |
Collapse
|
11
|
Roselli M, Ferroni P, Rolfo C, Peeters M, Palmirotta R, Formica V, Ludovici G, Laudisi A, De Marchis ML, La Farina F, Russo A, Guadagni F. TNF-α gene promoter polymorphisms and risk of venous thromboembolism in gastrointestinal cancer patients undergoing chemotherapy. Ann Oncol 2013; 24:2571-2575. [PMID: 23852308 DOI: 10.1093/annonc/mdt251] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023] Open
Abstract
BACKGROUND TNF-α has been proposed as a predictive factor for venous thromboembolism (VTE). Genetic polymorphisms could regulate TNF-α production. However, the relationship between TNFA gene variants and VTE is not clarified. This study aims to investigate the predictive role of five different TNFA gene promoter SNPs, or their haplotype combination(s), for a first VTE episode in gastrointestinal cancer out-patients treated with chemotherapy. PATIENTS AND METHODS Serum TNF-α levels and TNFA -863C/A, -857C/T, -376G/A, -308G/A and -238G/A gene promoter polymorphisms were retrospectively evaluated in 314 subjects, including 157 controls and 157 Caucasian patients with histologically diagnosed GI cancers beginning chemotherapy delivery (5-fluorouracil either as monotherapy or in combination with platinum compounds or irinotecan). RESULTS Haplotype analysis showed that a five-loci haplotype (CTGGG haplotype) has higher frequency in GI cancer patients who developed VTE (n = 15) during chemotherapy [odds ratio = 2.7, 95% confidence interval (CI) 1.04-7.11, P = 0.04]. GI patients who remained VTE-free did not differ in CTGGG haplotype frequency from controls. No association was observed between serum TNF-α levels and TNFA haplotype, but both were independent predictors of VTE. Approximately 20% of GI cancer patients carrying the CTGGG haplotype developed VTE compared with 4% of the remaining 101 patients (hazard ratio = 5.6, 95% CI 1.8-17.6, P = 0.003). CONCLUSION These results suggest that TNFA might represent a candidate gene contributing to VTE pathogenesis in GI cancer patients and suggest that VTE risk during chemotherapy might be genetically identified. Validation studies are needed for translation into clinical practice.
Collapse
Affiliation(s)
- M Roselli
- Medical Oncology, Department of System Medicine, Tor Vergata Clinical Center, University of Rome 'Tor Vergata', Rome
| | - P Ferroni
- Department of Advanced Biotechnologies and Bioimaging, IRCCS San Raffaele Pisana, Rome, Italy
| | - C Rolfo
- Phase I - Early Clinical Trials Unit, Department of Oncology, Antwerp University Hospital (UZA); MOCA (Multidisciplinary Oncology Center Antwerp), Antwerp University Hospital, Edegem, Belgium.
| | - M Peeters
- MOCA (Multidisciplinary Oncology Center Antwerp), Antwerp University Hospital, Edegem, Belgium
| | - R Palmirotta
- Department of Advanced Biotechnologies and Bioimaging, IRCCS San Raffaele Pisana, Rome, Italy
| | - V Formica
- Medical Oncology, Department of System Medicine, Tor Vergata Clinical Center, University of Rome 'Tor Vergata', Rome
| | - G Ludovici
- Department of Advanced Biotechnologies and Bioimaging, IRCCS San Raffaele Pisana, Rome, Italy
| | - A Laudisi
- Medical Oncology, Department of System Medicine, Tor Vergata Clinical Center, University of Rome 'Tor Vergata', Rome
| | - M L De Marchis
- Department of Advanced Biotechnologies and Bioimaging, IRCCS San Raffaele Pisana, Rome, Italy
| | - F La Farina
- Department of Advanced Biotechnologies and Bioimaging, IRCCS San Raffaele Pisana, Rome, Italy
| | - A Russo
- Section of Medical Oncology, Department of Surgical and Oncology Sciences, University of Palermo, Palermo, Italy
| | - F Guadagni
- Department of Advanced Biotechnologies and Bioimaging, IRCCS San Raffaele Pisana, Rome, Italy
| |
Collapse
|
12
|
Roselli M, Ferroni P, Riondino S, Mariotti S, Laudisi A, Vergati M, Cavaliere F, Palmirotta R, Guadagni F. Impact of chemotherapy on activated protein C-dependent thrombin generation--association with VTE occurrence. Int J Cancer 2013; 133:1253-8. [PMID: 23404208 DOI: 10.1002/ijc.28104] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2012] [Accepted: 02/01/2013] [Indexed: 12/21/2022]
Abstract
Chemotherapy has been associated with an increased risk of venous thromboembolism (VTE). However, the prevalence of coagulation abnormalities or VTE occurrence as a consequence of different anti-cancer agents or treatment schemes is largely uncharacterized. Thus, this study was aimed at analyzing the impact of different anticancer drugs on the prothrombotic status of cancer out-patients scheduled for chemotherapy. To this purpose, a mono-institutional study was prospectively conducted to monitor serial changes of activated protein C (APC) function in 505 consecutive cancer out-patients with primary or relapsing solid cancer at the start of a new chemotherapy regimen. The results obtained showed that age >65 years (p = 0.01), ECOG performance status (p = 0.01), platinum-based (p = 0.035) and fluoropyrimidine-based regimens (p = 0.008) were independent predictors of an acquired APC resistance during the first chemotherapy cycle. Multivariate model of Cox proportional hazards survival analysis demonstrated that a decline in APC functionality (HR = 2.4; p = 0.013) and platinum-based regimens (HR = 2.2; p = 0.042) were both capable of predicting the occurrence of a first VTE episode during chemotherapy. Indeed, 14% of patients with platinum-associated APC impairment had VTE over a 1-year follow-up, compared to 3% of patients treated with other regimens and in whom APC functionality remained stable (HR = 1.5; p = 0.003). We may, thus, conclude that use of platinum-based regimens is responsible for induction of an acquired thrombophilic condition and represents a predictor for VTE even after adjustment for other risk factors.
Collapse
Affiliation(s)
- Mario Roselli
- Department of System Medicine, Medical Oncology, Tor Vergata Clinical Center, University of Rome Tor Vergata, Rome, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Zinnamosca L, Laudisi A, Petramala L, Marinelli C, Roselli M, Vitolo D, Montesani C, Letizia C. von Hippel Lindau disease with colon adenocarcinoma, renal cell carcinoma and adrenal pheochromocytoma. Intern Med 2013; 52:1599-603. [PMID: 23857093 DOI: 10.2169/internalmedicine.52.8278] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
von Hippel-Lindau (VHL) disease is an autosomal dominant inherited tumor syndrome characterized by the presence of heterogeneous tumors derived from different organs. VHL is caused by germline mutations in the VHL tumor suppressor gene located on chromosome 3p25-26. The loss of functional VHL protein contributes to tumorigenesis. VHL tumors are most frequently derived from the kidneys, adrenal gland, central nervous system, eyes, inner ear, epididymis and pancreas. We herein describe the case of a 64-year-old man carrying the VHL gene mutation affected by simultaneous colon adenocarcinoma, renal clear cell carcinoma and adrenal pheochromocytoma.
Collapse
Affiliation(s)
- Laura Zinnamosca
- Department Unit of Secondary Hypertension, Department of Internal Medicine and Medical Specialities, "Sapienza" University of Rome, Italy
| | | | | | | | | | | | | | | |
Collapse
|
14
|
Ferroni P, Martini F, Portarena I, Grenga I, Riondino S, La Farina F, Laudisi A, Guadagni F, Roselli M. Early changes of a novel APC-dependent thrombin generation assay during chemotherapy independently predict venous thromboembolism in cancer patients—a pilot study. Support Care Cancer 2012; 20:2713-20. [DOI: 10.1007/s00520-012-1391-1] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2011] [Accepted: 01/25/2012] [Indexed: 01/05/2023]
|
15
|
Ferroni P, Martini F, Portarena I, Grenga I, Riondino S, La Farina F, Laudisi A, Roselli M, Guadagni F. An activated protein C-dependent thrombin generation assay predicts chemotherapy-associated venous thromboembolism in cancer patients. Thromb Haemost 2011; 105:931-2. [PMID: 21359410 DOI: 10.1160/th10-11-0757] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2010] [Accepted: 01/28/2011] [Indexed: 11/05/2022]
|
16
|
Palmirotta R, Ferroni P, Savonarola A, Martini F, Ciatti F, Laudisi A, Sini V, Del Monte G, Guadagni F, Roselli M. Prognostic value of pre-surgical plasma PAI-1 (plasminogen activator inhibitor-1) levels in breast cancer. Thromb Res 2009; 124:403-8. [DOI: 10.1016/j.thromres.2009.02.014] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2008] [Revised: 02/03/2009] [Accepted: 02/17/2009] [Indexed: 10/20/2022]
|
17
|
Guadagni F, Roselli M, Martini F, Spila A, Riondino S, D'Alessandro R, Del Monte G, Formica V, Laudisi A, Portarena I, Palmirotta R, Ferroni P. Prognostic significance of serum adipokine levels in colorectal cancer patients. Anticancer Res 2009; 29:3321-3327. [PMID: 19661351] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
BACKGROUND Adipokines may significantly influence the growth and proliferation of tumor stroma and malignant cells within. Reduced adiponectin and increased leptin serum levels were found in colorectal cancer (CRC) patients. Recently, it has been demonstrated that tumor necrosis factor-alpha (TNF-alpha) is able to induce dose-dependent changes in serum adipokine levels. Thus, aims of this study were to evaluate the possible associations between adipokines, TNF-alpha and clinicopathological variables of CRC patients and to analyze their possible prognostic value in predicting relapse-free and overall survival. MATERIALS AND METHODS Baseline leptin, adiponectin and TNF-alpha levels were analyzed in 90 patients with histologically diagnosed primary or newly diagnosed metastatic CRC treated at 'Tor Vergata' Clinical Center and followed up for a median period of 3 years. RESULTS Serum leptin levels were higher in CRC patients than in controls (p<0.0001). Conversely, serum adiponectin levels were lower in CRC patients than in controls (p<0.0001). Leptin inversely correlated with adiponectin (p<0.005). The leptin/adiponectin (L/A) ratio was eight-fold greater in CRC compared to controls (p<0.0001). Kaplan-Meier analysis of relapse-free and overall survival time showed that the L/A ratio was an independent predictor for adverse outcome in CRC. CONCLUSION Serum adipokine levels might have a role in the biology of CRC and the combined measurement of leptin and adiponectin levels might provide useful prognostic information in the management of patients with CRC.
Collapse
Affiliation(s)
- Fiorella Guadagni
- Department of Laboratory Medicine and Advanced Biotechnologies, IRCCS San Raffaele, Via della Pisana 235, 00163 Rome, Italy.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Franzese O, Adamo R, Pollicita M, Comandini A, Laudisi A, Perno CF, Aquaro S, Bonmassar E. Telomerase activity, hTERT expression, and phosphorylation are downregulated in CD4(+) T lymphocytes infected with human immunodeficiency virus type 1 (HIV-1). J Med Virol 2007; 79:639-46. [PMID: 17387751 DOI: 10.1002/jmv.20855] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Human immunodeficiency virus type 1 (HIV-1) infection is characterized by a progressive decrease of CD4(+) T cells accompanied by other immune dysfunctions. Telomerase is transiently activated in lymphocytes during activation and is able to compensate for the progressive telomeric loss that occurs at each cell division, contributing to ensure the telomere length necessary for multiple proliferative events. The effect of HIV-1 infection on telomerase activity and on the expression of some of the factors involved in its regulation in CD4(+) T cells was investigated. Telomerase was found to be downregulated in both nuclear and cytoplasmic compartments, together with an impairment of human telomerase reverse transcriptase (hTERT) expression and of the cell machinery involved in hTERT phosporylation.
Collapse
Affiliation(s)
- Ornella Franzese
- Department of Neuroscience, Section of Pharmacology and Medical Oncology, University of Rome Tor Vergata, Rome, Italy.
| | | | | | | | | | | | | | | |
Collapse
|
19
|
Palmirotta R, Ferroni P, Savonarola A, Martini F, Ciatti F, Laudisi A, Fossile E, Del Monte G, Guadagni F, Roselli M. PO-32 Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer. Thromb Res 2007. [DOI: 10.1016/s0049-3848(07)70185-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
20
|
De Rossi A, Rossi L, Laudisi A, Sini V, Toppo L, Marchesi F, Tortorelli G, Leti M, Turriziani M, Aquino A, Bonmassar E, De Vecchis L, Torino F. Focus on Fotemustine. J Exp Clin Cancer Res 2006; 25:461-8. [PMID: 17310834] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/14/2023]
Abstract
Fotemustine is a cytotoxic alkylating agent, belonging to the group of nitrosourea family. Its mechanism of action is similar to that of other nitrosoureas, characterized by a mono-functional/bi-functional alkylating activity. Worth of consideration is the finding that the presence of high levels of the DNA repair enzyme O6-methylguanine-DNA-methyltransferase (MGMT) in cancer cells confers drug resistance. In different clinical trials Fotemustine showed a remarkable antitumor activity as single agent, and in association with other antineoplastic compounds or treatment modalities. Moreover, its toxicity is generally considered acceptable. The drug has been employed in the treatment of metastatic melanoma, and, on the basis of its pharmacokinetic properties, in brain tumors, either primitive or metastatic. Moreover, Fotemustine shows pharmacodynamic properties similar to those of mono-functional alkylating compounds (e.g. DNA methylating drugs, such as Temozolomide), that have been recently considered for the management of acute refractory leukaemia. Therefore, it is reasonable to assume that this agent could be a good candidate to play a potential role in haematological malignancies.
Collapse
Affiliation(s)
- A De Rossi
- Department of Neuroscience, University of Rome "Tor Vergata", Italy
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Roselli M, Mariotti S, Ferroni P, Laudisi A, Mineo D, Pompeo E, Ambrogi V, Mineo TC. Postsurgical chemotherapy in stage IB nonsmall cell lung cancer: Long-term survival in a randomized study. Int J Cancer 2006; 119:955-60. [PMID: 16550600 DOI: 10.1002/ijc.21933] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Although surgical resection is considered the adequate treatment in early stages of nonsmall cell lung cancer, long-term survival is not satisfactory and recurrence rate is high. We previously showed that postoperative chemotherapy at stage IB reduces recurrences and prolongs overall survival. We extended size and observation period of the study sample and performed a separate analysis for minimally resected patients. The trial was designed as a randomized, 2-armed study with postoperative adjuvant chemotherapy versus surgery alone as control group. All patients had stage IB disease (pT2N0) assessed after a radical surgical procedure (defined as anatomical or minimal). Chemotherapy consisted of cisplatin (100 mg/m2 day 1) and etoposide (120 mg/m2 days 1-3) for 6 cycles. The primary endpoint was overall survival; secondary endpoint was disease-free survival (DFS). One hundred and forty patients entered the study: 70 were assigned to the adjuvant chemotherapy group and 70 to the control group. Groups were homogeneous for conventional risk factors. There was no clinically significant morbidity associated to chemotherapy. Patients were followed for a mean period of 40.31 +/- 30.86 months. A significant difference in overall (p = 0.02) and disease-free (p = 0.0001) survival was observed between patients undergoing adjuvant chemotherapy vs. control group. Adjuvant chemotherapy significantly improved both overall (p = 0.02) and DFS (p = 0.003) of anatomically resected patients, but only the DFS (p = 0.02) of minimally resected patients. Our results confirm that adjuvant chemotherapy may have a real impact on long-term survival in patients with stage IB nonsmall cell lung cancer being this effect especially evident for those anatomically resected.
Collapse
Affiliation(s)
- Mario Roselli
- Medical Oncology, Department of Internal Medicine, Policlinico Tor Vergata University, Rome, Italy.
| | | | | | | | | | | | | | | |
Collapse
|
22
|
Martini F, Ferroni P, Guadagni F, Basili S, Spila A, D'Alessandro R, Mineo D, Laudisi A, Portarena I, Mariotti S, Ambrogi V, Mineo TC, Roselli M. Plasma von Willebrand factor antigen levels in non-small cell lung cancer patients. Anticancer Res 2005; 25:403-7. [PMID: 15816602] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/02/2023]
Abstract
BACKGROUND To analyze the behavior of circulating von Willebrand factor antigen (vWf:Ag) in patients with non-small cell lung cancer (NSCLC). PATIENTS AND METHODS Pre-surgical vWf:Ag levels were measured in 64 patients with histologically diagnosed NSCLC compared to 64 patients with benign pulmonary diseases, as well as 64 age- and sex-matched controls. RESULTS Patients with NSCLC had mean vWf:Ag concentrations lower than either controls or benign patients (p =0.001). CEA was the only variable predictive of low vWf:Ag levels (p<0.01). Five of the 64 NSCLC patients had abnormally low vWf:Ag concentrations (<36 IU/dL). When these patients were excluded from the analysis, the vWf:Ag levels of NSCLC patients did not differ from those of controls (p=0.19). CONCLUSION The vWf antigen levels of NSCLC patients are not substantially altered. A small subset of these patients will have a depletion of circulating vWf:Ag, probably because of a paraneoplastic process associated with an advanced stage of disease.
Collapse
Affiliation(s)
- Francesca Martini
- Department of Experimental Medicine and Pathology, University La Sapienza, Viale Regina Elena 324, Rome, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Masala S, Roselli M, Massari F, Fiori R, Ursone A, Fossile E, Laudisi A, Simonetti G. Radiofrequency Heat Ablation and Vertebroplasty in the treatment of neoplastic vertebral body fractures. Anticancer Res 2004; 24:3129-33. [PMID: 15510600] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/01/2023]
Abstract
BACKGROUND Metastatic cancer is the most common malignant disease of the skeletal system. Traditionally, conventional fractionated external beam radiotherapy has been the treatment of choice. Recently, minimally invasive surgical techniques (MISS) have been added to the therapeutic armamentarium. The purpose of our study was to assess the effectiveness and safety of Radiofrequency Heat Ablation and Vertebroplasty in the treatment of neoplastic Vertebral Compressive Fractures (VCF). The aim of radiofrequency heat ablation is to destroy the tumor tissue before stabilizing the vertebra through the intrasomatic injection of cement. PATIENTS AND METHODS We treated patients with unremitting pain over spine, in absence of symptomatic spinal cord or roots compression and refractory to conventional therapeutic options such as radiation therapy, chemotherapy, surgery and use of analgesics. RESULTS The method demonstrated swift pain relief associated with an evident augmentation in the weight-bearing resistance. CONCLUSION The association of Radiofrequency Heat Ablation and Vertebroplasty is an effective, simple and safe treatment of vertebral collapse consequent to metastases.
Collapse
Affiliation(s)
- Salvatore Masala
- Departments of Interventional Radiology, University of Rome, Tor Vergata, Rome, Italy.
| | | | | | | | | | | | | | | |
Collapse
|